Apellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Results

Apellis Pharmaceuticals Misses on EPS — Stock Down 0.76%

This earnings report indicates that Apellis Pharmaceuticals is facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 0.76%, likely due to investor concerns over the lack of guidance and the ongoing financial performance. The absence of revenue figures adds to the uncertainty surrounding the company's current standing.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.56	N/A	-9.70%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing the importance of their ongoing projects. They did not provide specific guidance for the upcoming quarters.

Management did not provide specific guidance for future quarters.

The company is focused on advancing its pipeline despite the current challenges.

Apellis Pharmaceuticals Misses on EPS — Stock Down 0.76%

Key numbers

Management commentary

Apellis Pharmaceuticals, Inc.

More earnings this week

Apellis Pharmaceuticals Misses on EPS — Stock Down 0.76%

Key numbers

Management commentary